Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genmab ( (GMAB) ) just unveiled an update.
On November 19, 2025, Genmab A/S announced transactions involving shares and linked securities conducted by its managerial employees and their closely associated persons. These transactions, disclosed in accordance with market abuse regulations, involved the sale of 175 shares at an average price of DKK 1,960.35 across multiple exchanges. This announcement reflects the company’s transparency in financial dealings, potentially impacting stakeholder trust and market perception.
The most recent analyst rating on (GMAB) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance and positive earnings call sentiment are the primary drivers of its score. The company’s strategic initiatives and solid valuation further support its potential, despite some technical indicators suggesting caution.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, focused on developing innovative antibody therapeutics. Established in 1999, the company has a global presence across North America, Europe, and Asia Pacific. Genmab’s proprietary pipeline includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators, aiming to transform the lives of people with cancer and other serious diseases by 2030.
Average Trading Volume: 2,128,678
Technical Sentiment Signal: Buy
Current Market Cap: $18.85B
For detailed information about GMAB stock, go to TipRanks’ Stock Analysis page.